Aimmune Therapeutics
Aimmune Therapeutics, a clinical-stage biopharmaceutical company, is developing desensitization treatments to protect people with food allergies from the life-threatening consequences of accidental exposures to their allergens. We are currently conducting Phase 3 studies of our lead product, AR101 for the treatment of peanut allergy.